Linked Life Data

9262248

Source:http://linkedlifedata.com/resource/pubmed/id/9262248

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
15
pubmed:dateCreated
1997-8-28
pubmed:abstractText
It has been known for more than 20 years that estrogen replacement therapy substantially increases a woman's risk of developing endometrial cancer. To reduce this increased risk, progestins have been added to estrogen replacement therapy for between 5 and 15 days (usually 7 or 10 days) per "month" in a sequential fashion (sequential estrogen-progestin replacement therapy) or with each dose of estrogen replacement therapy (continuous combined replacement therapy). At the present time, however, little is known about the effects of varying the number of days that progestin is used in sequential estrogen-progestin replacement therapy.
pubmed:grant
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0027-8874
pubmed:author
pubmed:issnType
Print
pubmed:day
6
pubmed:volume
89
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1110-6
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
1997
pubmed:articleTitle
Estrogen-progestin replacement therapy and endometrial cancer.
pubmed:affiliation
Department of Preventive Medicine, USC/Norris Comprehensive Cancer Center, Los Angeles, CA 90033-0800, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.